{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:44:02Z","timestamp":1790981042376,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI111962"],"award-info":[{"award-number":["RO1 AI111962"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ijpddr.2024.100577","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T07:28:35Z","timestamp":1735198115000},"page":"100577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei"],"prefix":"10.1016","volume":"27","author":[{"given":"Leah A.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vision","family":"Bagonza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Bobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2024.100577_bib1","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1128\/AAC.00602-15","article-title":"Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr)","volume":"59","author":"Armstrong","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2024.100577_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006684","article-title":"Model system to define pharmacokinetic requirements for antimalarial drug efficacy","volume":"5","author":"Bakshi","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijpddr.2024.100577_bib4","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1128\/AAC.00529-07","article-title":"Pharmacodynamics of doxycycline in a murine malaria model","volume":"51","author":"Batty","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib5","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/AAC.02460-12","article-title":"Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth","volume":"57","author":"Bessoff","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1086\/381785","article-title":"Fosmidomycin-clindamycin for Plasmodium falciparum infections in african children","volume":"189","author":"Borrmann","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2024.100577_bib7","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1086\/424603","article-title":"Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria","volume":"190","author":"Borrmann","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2024.100577_bib8","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1128\/AAC.00392-06","article-title":"Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria","volume":"50","author":"Borrmann","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2125.2012.04292.x","article-title":"Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis","volume":"74","author":"Bouazza","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpddr.2024.100577_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00416-19","article-title":"Kinetic driver of antibacterial drugs against Plasmodium falciparum: implications for clinical dosing","author":"Caton","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.lfs.2016.06.030","article-title":"Understanding the biology of the Plasmodium falciparum apicoplast; an excellent target for antimalarial drug development","volume":"158","author":"Chakraborty","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.ijpddr.2024.100577_bib12","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-017-01352-3","article-title":"Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling","volume":"8","author":"Challenger","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpddr.2024.100577_bib13","doi-asserted-by":"crossref","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2024.100577_bib14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/AAC.16.6.710","article-title":"Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique","volume":"16","author":"Desjardins","year":"1979","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/clinids\/4.6.1133","article-title":"Clindamycin: a review of fifteen years of experience","volume":"4","author":"Dhawan","year":"1982","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2024.100577_bib16","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1128\/AAC.32.12.1825","article-title":"Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens","volume":"32","author":"Flaherty","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12936-019-3055-9","article-title":"Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages","volume":"18","author":"Flores-Garcia","year":"2019","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2024.100577_bib18","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.ijpara.2008.05.012","article-title":"Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites","volume":"38","author":"Franke-Fayard","year":"2008","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ijpddr.2024.100577_bib19","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1021\/jm400282d","article-title":"Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities","volume":"56","author":"Gorka","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2024.100577_bib20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/infdis\/jiw304","article-title":"Whole-genome sequencing to evaluate the resistance landscape following antimalarial treatment failure with fosmidomycin-clindamycin","volume":"214","author":"Guggisberg","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2024.100577_bib21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.exger.2009.06.006","article-title":"Age-dependent and gender-specific changes in mouse tissue iron by strain","volume":"44","author":"Hahn","year":"2009","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.ijpddr.2024.100577_bib22","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.07789","article-title":"Longitudinal analysis of Plasmodium sporozoite motility in the dermis reveals component of blood vessel recognition","volume":"4","author":"Hopp","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.ijpddr.2024.100577_bib23","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.285.5433.1573","article-title":"Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs","volume":"285","author":"Jomaa","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2024.100577_bib24","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the national Institutes of Health, and the HIV medicine association of the infectious diseases society of America","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm. Rep. (Morb. Mortal. Wkly. Rep.)"},{"key":"10.1016\/j.ijpddr.2024.100577_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ph15121553","article-title":"Over 40 Years of fosmidomycin drug Research: a comprehensive review and future opportunities","volume":"15","author":"Knak","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijpddr.2024.100577_bib26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12936-022-04170-1","article-title":"Need for optimized dosages in the design of comparative clinical trials of anti-malarial drugs","volume":"21","author":"Krishna","year":"2022","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2024.100577_bib27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1128\/AAC.03274-14","article-title":"Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model","volume":"59","author":"Lakshminarayana","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib28","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1128\/AAC.00018-12","article-title":"Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria","volume":"56","author":"Lanaspa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.47.2.735-738.2003","article-title":"Fosmidomycin, a novel chemotherapeutic agent for malaria","volume":"47","author":"Lell","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7205\/MILMED-D-16-00090","article-title":"Comparative susceptibility of different mouse strains to liver-stage infection with Plasmodium berghei sporozoites assessed using in vivo imaging","volume":"182","author":"Li","year":"2017","journal-title":"Mil. Med."},{"key":"10.1016\/j.ijpddr.2024.100577_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003665","article-title":"Toxoplasma gondii relies on both host and parasite isoprenoids and can be rendered sensitive to atorvastatin","volume":"9","author":"Li","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijpddr.2024.100577_bib32","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315069121","article-title":"Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism","volume":"121","author":"MacLeod","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpddr.2024.100577_bib33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/AAC.00878-07","article-title":"Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model","volume":"52","author":"Moore","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1128\/AAC.21.2.224","article-title":"Pharmacokinetics of fosmidomycin, a new phosphonic acid antibiotic","volume":"21","author":"Murakawa","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2875-6-70","article-title":"Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria","volume":"6","author":"Na-Bangchang","year":"2007","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2024.100577_bib36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1292\/jvms.10-0496","article-title":"Host cholesterol synthesis contributes to growth of intracellular Toxoplasma gondii in macrophages","volume":"73","author":"Nishikawa","year":"2011","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.ijpddr.2024.100577_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12936-022-04050-8","article-title":"Efficacy of 3-day low dose quinine plus clindamycin versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children (CLINDAQUINE): an open-label randomized trial","volume":"21","author":"Obonyo","year":"2022","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2024.100577_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00394-18","article-title":"Superior pyronaridine single-dose pharmacodynamics compared to artesunate, chloroquine, and amodiaquine in a murine malaria luciferase model","volume":"62","author":"Okoth","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib39","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.01448-06","article-title":"Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria","volume":"51","author":"Oyakhirome","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib40","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1128\/AAC.01463-12","article-title":"Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria","volume":"57","author":"Patel","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"Faseb. J."},{"key":"10.1016\/j.ijpddr.2024.100577_bib42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1475-2875-7-225","article-title":"Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria","volume":"7","author":"Ruangweerayut","year":"2008","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2024.100577_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000371","article-title":"Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence","volume":"2","author":"Schallig","year":"2017","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.ijpddr.2024.100577_bib44","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1128\/iai.62.11.4844-4847.1994","article-title":"Susceptibility of different strains of mice to hepatic infection with Plasmodium berghei","volume":"62","author":"Scheller","year":"1994","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijpddr.2024.100577_bib45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1126\/science.781840","article-title":"Human malaria parasites in continuous culture","volume":"193","author":"Trager","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2024.100577_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01161-17","article-title":"Validation of putative apicoplast-targeting drugs using a chemical supplementation assay in cultured human malaria parasites","volume":"62","author":"Uddin","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02499-16","article-title":"Impact of extended duration of artesunate treatment on parasitological outcome in a cytocidal murine malaria model","volume":"61","author":"Walker","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138204","article-title":"A systematic review and meta-analysis of the efficacy of anti-toxoplasma gondii medicines in humans","volume":"10","author":"Wei","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2024.100577_bib49","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1128\/AAC.00287-13","article-title":"Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization","volume":"57","author":"White","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib50","series-title":"WHO Guidelines for Malaria, 30 November 2024","year":"2024"},{"key":"10.1016\/j.ijpddr.2024.100577_bib51","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1128\/AAC.46.9.2889-2894.2002","article-title":"In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin","volume":"46","author":"Wiesner","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2024.100577_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2006.11.019","article-title":"Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability","volume":"332","author":"Yang","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpddr.2024.100577_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1475-2875-13-15","article-title":"Simple, sensitive and quantitative bioluminescence assay for determination of malaria pre-patent period","volume":"13","author":"Zuzarte-Luis","year":"2014","journal-title":"Malar. J."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320724000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320724000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T23:17:29Z","timestamp":1751930249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320724000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":53,"alternative-id":["S2211320724000587"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2024.100577","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2024.100577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}],"article-number":"100577"}}